Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00587457 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia
A Phase 1 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00587457 is a Phase 1 study that was terminated before completion, run by MedImmune. The registered enrollment target is 11 participants.
The verdict
NCT00587457, a Phase 1 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This was a multicenter, Phase 1, standard 3+3 dose-escalation study to evaluate the safety and anti-neoplastic activity of moxetumomab pasudotox in relapsed or refractory participants with chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL) or Small Lymphocytic Lymphoma (SLL).
Interventions
- DRUG CAT-8015 20 mcg/kg
- DRUG CAT-8015 5 mcg/kg
- DRUG CAT-8015 10 mcg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-03-07 |
| Est. Completion | 2008-04-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00587457
The ClinicalTrials.gov registry entry for NCT00587457 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CAT-8015 20 mcg/kg is the first listed.
NCT00587457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00587457 about?
NCT00587457 is a clinical study titled "A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia". This was a multicenter, Phase 1, standard 3+3 dose-escalation study to evaluate the safety and anti-neoplastic activity of moxetumomab pasudotox in relapsed or refractory participants with chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL) or Small Lymphocytic Lymphoma (SLL).
What is the current status of trial NCT00587457?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2007-03-07. Estimated completion is 2008-04-07.
What interventions are being tested in trial NCT00587457?
The interventions under investigation include: CAT-8015 20 mcg/kg (DRUG), CAT-8015 5 mcg/kg (DRUG), CAT-8015 10 mcg/kg (DRUG).
Who is sponsoring clinical trial NCT00587457?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.